-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$2.00-33.77% Downside
Cyteir Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Cyteir Therapeutics, Inc.?
Cyteir Therapeutics, Inc. has been rated by research analysts at Morgan Stanley in the past 90 days.